UPCOMING RIGHTS ISSUE IN STAYBLE THERAPEUTICS
Together with Sedermera Fondkommission and Markets and Corporate Law Nordic AB, Stayble will perform a rights issue. The Board of Directors has resolved on a new issue of shares in which the public is also given the opportunity to participate . The rights issue can provide the Company with a maximum of approximately SEK 41.5 million before issue costs. In total, the Company has thus received subscription and guarantee commitments corresponding to approximately 84 percent of the rights issue. Prior to the rights issue, existing shareholders and external investors have entered subscription commitments totaling approximately SEK 19.8 million (corresponding to approximately 48 percent of the rights issue). In addition, Stayble has procured guarantee (so-called top-down or top guarantee) of a total of approximately SEK 15 million (corresponding to approximately 36 percent of the rights issue).Read more about the Rights Issue
Latest press releases
Stayble Therapeutic’s rights issue oversubscribed
The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 perc...
Information about the trading in subscription rights and BTA
Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection with the Company's ong...
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you email@example.com